The online home for the primary care professionals managing patients with cardiovascular disease, diabetes and related diseases.

Editorial: Sacubitril/valsartan in heart failure – a guide for primary care

Publication date: Monday, 21 November 2016
Contributor(s): Jan Procter-King, Mike Kirby

HF has a major impact on patients, their families, the NHS and social care services. It still has a poor prognosis, worse than many of the common cancers that also affect older people. It causes significant morbidity and imposes a major cost burden on the health service. This editorial provides an introduction to a special supplement on a first-in-class oral treatment for heart failure.

Sponsorship information:
This sponsored supplement was initiated and funded by Novartis. Novartis reviewed the supplement for technical accuracy and suitability within the ABPI Code of Practice. Final editorial control rests with the authors and editors.
Topics covered:
Category: Editorial
Edition: Volume 9 Number 1 Oct-Nov-Dec 2016
Contributor(s): Jan Procter-King, Mike Kirby

Article search and filter